首页 | 本学科首页   官方微博 | 高级检索  
检索        

紫杉醇联合卡铂治疗晚期非小细胞肺癌
引用本文:关琦,曲洪澜,陶丽艳,辛国祥.紫杉醇联合卡铂治疗晚期非小细胞肺癌[J].内蒙古医学杂志,2004,36(2):86-87.
作者姓名:关琦  曲洪澜  陶丽艳  辛国祥
作者单位:内蒙古林业总医院肿瘤科,内蒙古,牙克石,022150
摘    要:目的:评价国产紫杉醇联合卡铂治疗晚期非小细胞肺癌的临床疗效。方法:30例晚期非小细胞肺癌患者应用紫杉醇135mg/m^23~5h静脉滴注,卡铂300~350mg/m^2静脉滴注,每3周重复,进行3~4周期。结果:总有效率45%,平均生存期9.6个月,1年生存率35%,主要毒副反应是骨髓抑制,轻度恶心、呕吐、关节肌肉酸痛,未见严重过敏反应。结论:国产紫杉醇联合卡铂治疗晚期非小细胞肺癌有效率高,不良反应可耐受。

关 键 词:紫杉醇  卡铂  非小细胞肺癌  化学疗法
文章编号:1004-0951(2004)02-0086-02

Combined Treatment of Paclitaxel and Carboplation for Late Non-small Cell Lung Cancer
Guan Qi,QU Hong-lan,TAO Li-yan,XIN Guo-xiang.Combined Treatment of Paclitaxel and Carboplation for Late Non-small Cell Lung Cancer[J].Inner Mongolia Medical Journal,2004,36(2):86-87.
Authors:Guan Qi  QU Hong-lan  TAO Li-yan  XIN Guo-xiang
Institution:GUAN Qi,QU Hong-lan,TAO Li-yan,XIN Guo-xiangWT5BX
Abstract:HTSSObjective:To evaluate the efficacy of national paditaxel plus carboplation for late non-small cell lung cancer(NSCLC) .Methods:For 30 patients with late NSCLC,paclitaxel,135mg/m 2,int ravenous drip between 3 and 5 hours,carboplalion,300 to 350mg/m 2,intravenous d rip,every 3 weeks,the course was 9 to 12 weeks.Results:The total e ffective rate was 45%.The mean survival time was 9.6 months.The survival rate in 1 year was 35%.The major side effects were arrest of bone marrow,mild nausea and vomiting,aching pain in joint and muscle,non alleagic reaction.Conclusi on:Combined treatment of national paclitaxel and carboplation is effectiv e for late NSCLC,with tolerable side effect.
Keywords:Paclitaxel  Carboplation  Non-small cell cancer(NSCLC)  Chemotherapy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号